Copyright Reports & Markets. All rights reserved.

Global Biologics CDMO Services Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Biologics CDMO Services by Type
    • 1.3.1 Overview: Global Biologics CDMO Services Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Biologics CDMO Services Consumption Value Market Share by Type in 2025
    • 1.3.3 Cell and Gene Therapies
    • 1.3.4 Antibodies
    • 1.3.5 Vaccines
    • 1.3.6 Other
  • 1.4 Global Biologics CDMO Services Market by Application
    • 1.4.1 Overview: Global Biologics CDMO Services Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 SMBs
    • 1.4.3 Large Companies
  • 1.5 Global Biologics CDMO Services Market Size & Forecast
  • 1.6 Global Biologics CDMO Services Market Size and Forecast by Region
    • 1.6.1 Global Biologics CDMO Services Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Biologics CDMO Services Market Size by Region, (2021-2032)
    • 1.6.3 North America Biologics CDMO Services Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Biologics CDMO Services Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Biologics CDMO Services Market Size and Prospect (2021-2032)
    • 1.6.6 South America Biologics CDMO Services Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Biologics CDMO Services Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Lonza
    • 2.1.1 Lonza Details
    • 2.1.2 Lonza Major Business
    • 2.1.3 Lonza Biologics CDMO Services Product and Solutions
    • 2.1.4 Lonza Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Lonza Recent Developments and Future Plans
  • 2.2 Catalent
    • 2.2.1 Catalent Details
    • 2.2.2 Catalent Major Business
    • 2.2.3 Catalent Biologics CDMO Services Product and Solutions
    • 2.2.4 Catalent Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Catalent Recent Developments and Future Plans
  • 2.3 Samsung Biologics
    • 2.3.1 Samsung Biologics Details
    • 2.3.2 Samsung Biologics Major Business
    • 2.3.3 Samsung Biologics Biologics CDMO Services Product and Solutions
    • 2.3.4 Samsung Biologics Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Samsung Biologics Recent Developments and Future Plans
  • 2.4 FUJIFILM Diosynth Biotechnologies
    • 2.4.1 FUJIFILM Diosynth Biotechnologies Details
    • 2.4.2 FUJIFILM Diosynth Biotechnologies Major Business
    • 2.4.3 FUJIFILM Diosynth Biotechnologies Biologics CDMO Services Product and Solutions
    • 2.4.4 FUJIFILM Diosynth Biotechnologies Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans
  • 2.5 Boehringer Ingelheim
    • 2.5.1 Boehringer Ingelheim Details
    • 2.5.2 Boehringer Ingelheim Major Business
    • 2.5.3 Boehringer Ingelheim Biologics CDMO Services Product and Solutions
    • 2.5.4 Boehringer Ingelheim Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Boehringer Ingelheim Recent Developments and Future Plans
  • 2.6 WuXi Biologics
    • 2.6.1 WuXi Biologics Details
    • 2.6.2 WuXi Biologics Major Business
    • 2.6.3 WuXi Biologics Biologics CDMO Services Product and Solutions
    • 2.6.4 WuXi Biologics Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 WuXi Biologics Recent Developments and Future Plans
  • 2.7 Recipharm
    • 2.7.1 Recipharm Details
    • 2.7.2 Recipharm Major Business
    • 2.7.3 Recipharm Biologics CDMO Services Product and Solutions
    • 2.7.4 Recipharm Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Recipharm Recent Developments and Future Plans
  • 2.8 Thermo Fisher Scientific
    • 2.8.1 Thermo Fisher Scientific Details
    • 2.8.2 Thermo Fisher Scientific Major Business
    • 2.8.3 Thermo Fisher Scientific Biologics CDMO Services Product and Solutions
    • 2.8.4 Thermo Fisher Scientific Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Thermo Fisher Scientific Recent Developments and Future Plans
  • 2.9 AGC Biologics
    • 2.9.1 AGC Biologics Details
    • 2.9.2 AGC Biologics Major Business
    • 2.9.3 AGC Biologics Biologics CDMO Services Product and Solutions
    • 2.9.4 AGC Biologics Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 AGC Biologics Recent Developments and Future Plans
  • 2.10 Rentschler Biopharma
    • 2.10.1 Rentschler Biopharma Details
    • 2.10.2 Rentschler Biopharma Major Business
    • 2.10.3 Rentschler Biopharma Biologics CDMO Services Product and Solutions
    • 2.10.4 Rentschler Biopharma Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Rentschler Biopharma Recent Developments and Future Plans
  • 2.11 KBI Biopharma
    • 2.11.1 KBI Biopharma Details
    • 2.11.2 KBI Biopharma Major Business
    • 2.11.3 KBI Biopharma Biologics CDMO Services Product and Solutions
    • 2.11.4 KBI Biopharma Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 KBI Biopharma Recent Developments and Future Plans
  • 2.12 Siegfried
    • 2.12.1 Siegfried Details
    • 2.12.2 Siegfried Major Business
    • 2.12.3 Siegfried Biologics CDMO Services Product and Solutions
    • 2.12.4 Siegfried Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Siegfried Recent Developments and Future Plans
  • 2.13 Aenova Group
    • 2.13.1 Aenova Group Details
    • 2.13.2 Aenova Group Major Business
    • 2.13.3 Aenova Group Biologics CDMO Services Product and Solutions
    • 2.13.4 Aenova Group Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Aenova Group Recent Developments and Future Plans
  • 2.14 GenScript
    • 2.14.1 GenScript Details
    • 2.14.2 GenScript Major Business
    • 2.14.3 GenScript Biologics CDMO Services Product and Solutions
    • 2.14.4 GenScript Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 GenScript Recent Developments and Future Plans
  • 2.15 ProBioGen
    • 2.15.1 ProBioGen Details
    • 2.15.2 ProBioGen Major Business
    • 2.15.3 ProBioGen Biologics CDMO Services Product and Solutions
    • 2.15.4 ProBioGen Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 ProBioGen Recent Developments and Future Plans
  • 2.16 Northway Biotech
    • 2.16.1 Northway Biotech Details
    • 2.16.2 Northway Biotech Major Business
    • 2.16.3 Northway Biotech Biologics CDMO Services Product and Solutions
    • 2.16.4 Northway Biotech Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Northway Biotech Recent Developments and Future Plans
  • 2.17 3P Biopharmaceuticals
    • 2.17.1 3P Biopharmaceuticals Details
    • 2.17.2 3P Biopharmaceuticals Major Business
    • 2.17.3 3P Biopharmaceuticals Biologics CDMO Services Product and Solutions
    • 2.17.4 3P Biopharmaceuticals Biologics CDMO Services Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 3P Biopharmaceuticals Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Biologics CDMO Services Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Biologics CDMO Services by Company Revenue
    • 3.2.2 Top 3 Biologics CDMO Services Players Market Share in 2025
    • 3.2.3 Top 6 Biologics CDMO Services Players Market Share in 2025
  • 3.3 Biologics CDMO Services Market: Overall Company Footprint Analysis
    • 3.3.1 Biologics CDMO Services Market: Region Footprint
    • 3.3.2 Biologics CDMO Services Market: Company Product Type Footprint
    • 3.3.3 Biologics CDMO Services Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Biologics CDMO Services Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Biologics CDMO Services Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Biologics CDMO Services Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Biologics CDMO Services Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Biologics CDMO Services Consumption Value by Type (2021-2032)
  • 6.2 North America Biologics CDMO Services Market Size by Application (2021-2032)
  • 6.3 North America Biologics CDMO Services Market Size by Country
    • 6.3.1 North America Biologics CDMO Services Consumption Value by Country (2021-2032)
    • 6.3.2 United States Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Biologics CDMO Services Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Biologics CDMO Services Consumption Value by Type (2021-2032)
  • 7.2 Europe Biologics CDMO Services Consumption Value by Application (2021-2032)
  • 7.3 Europe Biologics CDMO Services Market Size by Country
    • 7.3.1 Europe Biologics CDMO Services Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 7.3.3 France Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Biologics CDMO Services Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Biologics CDMO Services Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Biologics CDMO Services Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Biologics CDMO Services Market Size by Region
    • 8.3.1 Asia-Pacific Biologics CDMO Services Consumption Value by Region (2021-2032)
    • 8.3.2 China Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 8.3.5 India Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Biologics CDMO Services Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Biologics CDMO Services Consumption Value by Type (2021-2032)
  • 9.2 South America Biologics CDMO Services Consumption Value by Application (2021-2032)
  • 9.3 South America Biologics CDMO Services Market Size by Country
    • 9.3.1 South America Biologics CDMO Services Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Biologics CDMO Services Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Biologics CDMO Services Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Biologics CDMO Services Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Biologics CDMO Services Market Size by Country
    • 10.3.1 Middle East & Africa Biologics CDMO Services Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Biologics CDMO Services Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Biologics CDMO Services Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Biologics CDMO Services Market Drivers
  • 11.2 Biologics CDMO Services Market Restraints
  • 11.3 Biologics CDMO Services Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Biologics CDMO Services Industry Chain
  • 12.2 Biologics CDMO Services Upstream Analysis
  • 12.3 Biologics CDMO Services Midstream Analysis
  • 12.4 Biologics CDMO Services Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Biologics CDMO Services market size was valued at US$ 32400 million in 2025 and is forecast to a readjusted size of US$ 74760 million by 2032 with a CAGR of 12.8% during review period.
    Biologics CDMO Services refer to the specialized contract development and manufacturing services provided by a Contract Development and Manufacturing Organization (CDMO) for biologic drugs. Biologics are complex medicines made from living cells or organisms, such as proteins, monoclonal antibodies, vaccines, and cell or gene therapies.
    Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.
    Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.
    Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.
    To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.
    The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.
    Biologics CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.
    CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.
    This report is a detailed and comprehensive analysis for global Biologics CDMO Services market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Biologics CDMO Services market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Biologics CDMO Services market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Biologics CDMO Services market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Biologics CDMO Services market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Biologics CDMO Services
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Biologics CDMO Services market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Biologics CDMO Services market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Cell and Gene Therapies
    Antibodies
    Vaccines
    Other
    Market segment by Application
    SMBs
    Large Companies
    Market segment by players, this report covers
    Lonza
    Catalent
    Samsung Biologics
    FUJIFILM Diosynth Biotechnologies
    Boehringer Ingelheim
    WuXi Biologics
    Recipharm
    Thermo Fisher Scientific
    AGC Biologics
    Rentschler Biopharma
    KBI Biopharma
    Siegfried
    Aenova Group
    GenScript
    ProBioGen
    Northway Biotech
    3P Biopharmaceuticals
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Biologics CDMO Services product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Biologics CDMO Services, with revenue, gross margin, and global market share of Biologics CDMO Services from 2021 to 2026.
    Chapter 3, the Biologics CDMO Services competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biologics CDMO Services market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics CDMO Services.
    Chapter 13, to describe Biologics CDMO Services research findings and conclusion.

    Buy now